These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 29038654)

  • 21. Activation of dendritic cells and induction of T cell responses by HPV 16 L1/E7 chimeric virus-like particles are enhanced by CpG ODN or sorbitol.
    Freyschmidt EJ; Alonso A; Hartmann G; Gissmann L
    Antivir Ther; 2004 Aug; 9(4):479-89. PubMed ID: 15456078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The adjuvant effect of CpG oligodeoxynucleotide linked to the non-toxic B subunit of cholera toxin for induction of immunity against H. pylori in mice.
    Nyström-Asklin J; Adamsson J; Harandi AM
    Scand J Immunol; 2008 May; 67(5):431-40. PubMed ID: 18298617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of oral administration of CpG ODN-OVA on WBB6F1-W/Wv mice.
    Teshima R; Okunuki H; Sato Y; Akiyama H; Maitani T; Sawada J
    Allergol Int; 2006 Mar; 55(1):43-8. PubMed ID: 17075285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation.
    Vollmer J; Weeratna RD; Jurk M; Samulowitz U; McCluskie MJ; Payette P; Davis HL; Schetter C; Krieg AM
    Immunology; 2004 Oct; 113(2):212-23. PubMed ID: 15379982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CpG motifs of bacterial DNA exert protective effects in mouse models of IBD by antigen-independent tolerance induction.
    Bleich A; Janus LM; Smoczek A; Westendorf AM; Strauch U; Mähler M; Hedrich HJ; Fichtner-Feigl S; Schölmerich J; Falk W; Hofmann C; Obermeier F
    Gastroenterology; 2009 Jan; 136(1):278-87. PubMed ID: 18952084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deoxycytidyl-deoxyguanosine oligonucleotide classes A, B, and C induce distinct cytokine gene expression patterns in rhesus monkey peripheral blood mononuclear cells and distinct alpha interferon responses in TLR9-expressing rhesus monkey plasmacytoid dendritic cells.
    Abel K; Wang Y; Fritts L; Sanchez E; Chung E; Fitzgerald-Bocarsly P; Krieg AM; Miller CJ
    Clin Diagn Lab Immunol; 2005 May; 12(5):606-21. PubMed ID: 15879022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improving the therapeutic index of CpG oligodeoxynucleotides by intralymphatic administration.
    von Beust BR; Johansen P; Smith KA; Bot A; Storni T; Kündig TM
    Eur J Immunol; 2005 Jun; 35(6):1869-76. PubMed ID: 15909311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epicutaneous application of CpG oligodeoxynucleotides with peptide or protein antigen promotes the generation of CTL.
    Klimuk SK; Najar HM; Semple SC; Aslanian S; Dutz JP
    J Invest Dermatol; 2004 Apr; 122(4):1042-9. PubMed ID: 15102096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvant activity of CpG-ODN formulated as a liquid crystal.
    Sánchez Vallecillo MF; Ullio Gamboa GV; Palma SD; Harman MF; Chiodetti AL; Morón G; Allemandi DA; Pistoresi-Palencia MC; Maletto BA
    Biomaterials; 2014 Mar; 35(8):2529-42. PubMed ID: 24382332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytidine-phosphate-guanosine oligonucleotides induce interleukin-8 production through activation of TLR9, MyD88, NF-κB, and ERK pathways in odontoblast cells.
    He W; Zhang Y; Zhang J; Yu Q; Wang P; Wang Z; Smith AJ
    J Endod; 2012 Jun; 38(6):780-5. PubMed ID: 22595112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
    Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
    Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CpG oligonucleotides as adjuvant in therapeutic vaccines against parasitic infections.
    Zimmermann S; Dalpke A; Heeg K
    Int J Med Microbiol; 2008 Jan; 298(1-2):39-44. PubMed ID: 17716944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vaccinations with T-helper type 1 directing adjuvants have different suppressive effects on the development of allergen-induced T-helper type 2 responses.
    Trujillo-Vargas CM; Mayer KD; Bickert T; Palmetshofer A; Grunewald S; Ramirez-Pineda JR; Polte T; Hansen G; Wohlleben G; Erb KJ
    Clin Exp Allergy; 2005 Aug; 35(8):1003-13. PubMed ID: 16120081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systemic innate immune responses following intrapulmonary delivery of CpG oligodeoxynucleotides in sheep.
    Nichani AK; Dar MA; Krieg AM; Mirakhur KK; Kaushik RS; Griebel PJ; Manuja A; Townsend HG; Babiuk LA; Mutwiri GK
    Vet Immunol Immunopathol; 2007 Feb; 115(3-4):357-68. PubMed ID: 17194483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytosolic Delivery of Thiolated Neoantigen Nano-Vaccine Combined with Immune Checkpoint Blockade to Boost Anti-Cancer T Cell Immunity.
    Zhang D; Lin Z; Wu M; Cai Z; Zheng Y; He L; Li Z; Zhou J; Sun L; Chen G; Zeng Y; Li J; Liu J; Yang H; Liu X
    Adv Sci (Weinh); 2021 Mar; 8(6):2003504. PubMed ID: 33747739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Orally administered OVA/CpG-ODN induces specific mucosal and systemic immune response in young and aged mice.
    Alignani D; Maletto B; Liscovsky M; Rópolo A; Morón G; Pistoresi-Palencia MC
    J Leukoc Biol; 2005 Jun; 77(6):898-905. PubMed ID: 15758079
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands.
    Shafique M; Wilschut J; de Haan A
    Vaccine; 2012 Jan; 30(3):597-606. PubMed ID: 22120195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma.
    Jacobs C; Duewell P; Heckelsmiller K; Wei J; Bauernfeind F; Ellermeier J; Kisser U; Bauer CA; Dauer M; Eigler A; Maraskovsky E; Endres S; Schnurr M
    Int J Cancer; 2011 Feb; 128(4):897-907. PubMed ID: 20473889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity.
    Suzuki Y; Wakita D; Chamoto K; Narita Y; Tsuji T; Takeshima T; Gyobu H; Kawarada Y; Kondo S; Akira S; Katoh H; Ikeda H; Nishimura T
    Cancer Res; 2004 Dec; 64(23):8754-60. PubMed ID: 15574787
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity.
    Vollmer J; Weeratna RD; Jurk M; Davis HL; Schetter C; Wüllner M; Wader T; Liu M; Kritzler A; Krieg AM
    J Leukoc Biol; 2004 Sep; 76(3):585-93. PubMed ID: 15218053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.